NIG
RARE icon

NFJ Investment Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

NFJ Investment Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37,667
Closed -$1.36M – 295
2025
Q1 		$1.36M Hold
37,667
– – 0.05% 235
2024
Q4 		$1.58M Sell
37,667
-464
-1% -$23K 0.05% 223
2024
Q3 		$2.12M Sell
38,131
-1,762
-4% -$89.8K 0.06% 205
2024
Q2 		$1.64M Sell
39,893
-4,069
-9% -$174K 0.05% 206
2024
Q1 		$2.05M Sell
43,962
-122
-0.3% -$5.75K 0.06% 189
2023
Q4 		$2.11M Buy
+44,084
New +$1.71M 0.06% 182

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

NFJ Investment Group's RARE Position: Q2 2025 in Review

NFJ Investment Group sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 37,667 shares — an estimated $1.36M sold.

NFJ Investment Group first reported a position in RARE in Q4 2023 and held it in 6 quarters. The position peaked at $2.12M in Q3 2024. 309 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

  • NFJ Investment Group reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • NFJ Investment Group sold 37,667 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $1.36M.
  • NFJ Investment Group first reported a position in Ultragenyx Pharmaceutical in Q4 2023 and held it in 6 quarters.
  • NFJ Investment Group's Ultragenyx Pharmaceutical position peaked at $2.12M in Q3 2024.
  • 309 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on NFJ Investment Group's 13F filing for Q2 2025, filed 14 Aug 2025.